Ironwood Pharmaceuticals Downgraded to 'Sell' Amid Falling Sales and Pipeline Setbacks

Key Facts

1Ironwood Pharmaceuticals was downgraded from 'Buy' to 'Sell'.

2LINZESS U.S. sales dropped 6% to $864.5M in 2025.

3The company declined to exercise its option on CNP-104 after disappointing data, removing a key pipeline catalyst.

Ironwood Pharmaceuticals (IRWD) has seen its stock rating downgraded from 'Buy' to 'Sell' following significant operational and clinical challenges. The company's primary product, LINZESS, reported a 6% decline in U.S. sales, falling to $864.5 million in 2025. Further complicating the outlook, Ironwood declined to exercise its option on the CNP-104 drug candidate after disappointing data results. This decision removes a crucial catalyst from the company's development pipeline, raising concerns about future revenue growth. Analysts have also expressed skepticism regarding management's ability to meet ambitious sales targets set for 2026. The combination of declining revenue and pipeline failures suggests a bearish outlook for the pharmaceutical firm in the near term.